Study highlights benefits of preventive antiepileptic treatment in infants with TSC

Preventive antiepileptic treatment in infants with tuberous sclerosis complex (TSC) modifies the natural history of epilepsy, reducing the risk and severity, according to new study findings.

About 70-90% of children with TSC develop epilepsy, which is often resistant to medication. In the multicenter EPISTOP trial, researchers compared the efficacy and safety of preventive versus conventional antiepileptic treatment in infants with TSC.

Presenting at ICNA/CNS 2020, Dr Katarzyna Kotulska-Jozwiak from the Children’s Memorial Health Institute, in Warsaw, Poland, said 94 infants with TSC without a seizure history were followed until 2 years of age with monthly video EEG.

They received antiepileptic treatment with vigabatrin either as conventional treatment (started after the first electrographic of clinical seizure) or preventively (if epileptiform EEG activity before seizures was detected).

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.